Phaxiam Therapeutics annual return on equity
2022
2023
Phaxiam Therapeutics Return on Equity (ROE) Growth & History (PHXM)
Phaxiam Therapeutics's return on equity was −95.68% for fiscal 2023.
View full Phaxiam Therapeutics company overviewPhaxiam Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −95.68% | −94.69 pp |
| 2022 | 2022-12-31 | −0.98% | — |
Phaxiam Therapeutics return on equity trends
Between the periods ended 2022-12-31 and 2023-12-31, Phaxiam Therapeutics's return on equity decreased from −0.98% to −95.68%, a change of −94.69 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Phaxiam Therapeutics source filings ↗